Previous studies have confirmed that PKC-δ can be involved in the regulation of the course of NASH through ERS pathway, and downregulated expression of PKC-δ have been useful in reducing the expression levels of ERS-related molecules, decreasing concentration of blood lipid and ALT in NASH or diabetic mice, in order to improving hepatic steatosis and fibrosis [12, 51–53]. This evidence concerns the gene GPT and fatty liver disease.